Poetsch JH
Dahlke C
Zinser ME
Kasonta R
Lunemann S
Rechtien A
Ly ML
Stubbe HC
Krahling V
Biedenkopf N
Eickmann M
Fehling SK
Olearo F
Strecker T
Sharma P
Lang KS
Lohse AW
Schmiedel S
Becker S
VSV-Ebola Consortium
Addo MM
J Infect Dis. 2019;219556-561
In response to the Ebola virus (EBOV) crisis of 2013-2016, a recombinant vesicular stomatitis virus (VSV)-based EBOV vaccine was clinically tested (NCT02283099). A single-dose regimen of VSV-EBOV revealed a safe and immunogenic profile and demonstrated clinical efficacy. While EBOV-specific immune responses to this candidate vaccine have previously been investigated, limited human data on immunity to the VSV vector are available. Within the scope of a phase 1 study, we performed a comprehensive longitudinal analysis of adaptive immune responses to internal VSV proteins following VSV-EBOV immunization. While no preexisting immunity to the vector was observed, more than one-third of subjects developed VSV-specific cytotoxic T-lymphocyte responses and antibodies.
